NODATNew-Onset Diabetes After Transplantation
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Furthermore, they were conducted using the old criteria for NODAT diagnosis.
In a study using data from the United States Renal Data System (USRDS), 21,489 patients were enrolled, of whom 4,105 developed NODAT by 3 years after transplant.
Higher body mass index (BMI) has been associated with increased risk for NODAT [2].
To investigate the incidence of and clinical and genetic risk factors that may predispose to the occurrence of NODAT in renal allograft recipients at Groote Schuur Hospital, Cape Town, South Africa (SA).
Several clinical characteristics of the study population were analysed to determine whether they were associated with an increased risk of NODAT in this cohort.
Existing preoperative cirrhotic complications, such as ascites, esophageal varices, and hepatic coma, were risk factors for post-LT NODAT. In Western countries, the three major risk factors of NODAT are HCV infection, obesity, and
The extent to which the immunosuppressive agents may induce diabetes is extremely variable, so that the choice of immunosuppressive therapy may have a strong impact on recipient's risk to develop a NODAT. In the metanalysis performed by Montori et al.
Reduced antihyperlipidaemic drug need was only evident with TAC, whereas the reduction in NODAT requiring any treatment was only evident with CsA.
Abbreviations ADA: American Diabetes Association BMI: Body mass index CTx: Cardiac transplant CVD: Cardiovascular disease eGFR: excreted glomerular filtration rate HBA1C: Glycated hemoglobin ISHLT: International Society of Heart and Lung Transplant MPA: Mycophenolate acid NODAT: New-onset diabetes after transplantation OGTT: Oral glucose tolerance test PTDM: Posttransplant diabetes mellitus.
The precise incidence of NODAT is difficult to determine, with a widely dispersed reported incidence between 2% and 50% [7], due to the lack of a uniform definition, varying immunosuppressive regimens, and variable duration of follow-up [1, 8].